Showing 1 - 5 results of 5 for search 'Jeffrey E Lancet', query time: 0.03s
Refine Results
-
1
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia by Judith E Karp, Jeffrey E Lancet
Published 2008-09-01
Article -
2
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi... by Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prebet
Published 2022-10-01
Article -
3
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML by Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Published 2021-07-01
Article -
4
Integrative molecular subtypes of acute myeloid leukemia by Qianxing Mo, Seongseok Yun, David A. Sallman, Nicole D. Vincelette, Guang Peng, Ling Zhang, Jeffrey E. Lancet, Eric Padron
Published 2023-05-01
Article -
5
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome by Rami S. Komrokji, Avani M. Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E. Lancet, David A. Sallman
Published 2022-11-01
Article